Related Experiment Videos
Summary
This study found that ethambutol, used in tuberculosis treatment at a mean dosage of 14.4 mg/kg, did not cause ocular toxicity or affect intra-ocular pressure in Korean patients. Ophthalmological assessments confirmed safety in the studied dosage range.
Area of Science:
- Ophthalmology
- Pharmacology
- Infectious Diseases
Background:
- Tuberculosis (TB) treatment often involves ethambutol.
- Potential ocular side effects of ethambutol necessitate careful monitoring.
- Understanding ethambutol's impact on intra-ocular pressure (IOP) is crucial for patient safety.
Purpose of the Study:
- To evaluate the ocular toxicity of ethambutol in Korean patients with tuberculosis.
- To determine if ethambutol, at a mean dosage of 14.4 mg/kg, affects intra-ocular pressure.
Main Methods:
- A pair-matched study design comparing patients receiving ethambutol with those on other anti-TB chemotherapy.
- Comprehensive ophthalmological assessments including fundi examination, visual fields, and macular thresholds.
- Measurement of intra-ocular pressures before and after a water-drinking test, with the ophthalmologist blinded to treatment allocation.
Main Results:
- No evidence of ocular toxicity was observed in the ethambutol group.
- Ethambutol, at the studied dosage, did not demonstrate a significant effect on intra-ocular pressure.
- The water-drinking test results were consistent across both treatment groups.
Conclusions:
- Ethambutol is safe regarding ocular toxicity and IOP at a mean dosage of 14.4 mg/kg in Korean TB patients.
- Routine ophthalmological assessments are important for TB patients undergoing ethambutol therapy.
- Further research may explore long-term effects or higher dosages of ethambutol.